公开(公告)号：US20230111593A1

公开(公告)日：2023-04-13

申请号：US17799171

申请日：2021-02-12

申请人： NOVARTIS AG ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Stephen SCHUSTER ,  Yubing TONG ,  Jayaram K. UDUPA ,  Drew A. TORIGIAN

IPC分类号： G16H50/50 ,  A61K35/17 ,  A61K38/17 ,  A61P35/00 ,  G06V10/82 ,  G06V10/764 ,  G06T7/00

摘要： This disclosure provides methods and systems for determining a lesion-level treatment response to a chimeric antigen receptor (CAR) therapy, e.g., a CAR CD19 therapy, and uses of said methods and systems for evaluating the responsiveness of a subject to a CAR CD19 therapy, and for treating a subject with a CAR CD19 therapy.

公开(公告)号：US20230090389A1

公开(公告)日：2023-03-23

申请号：US17905032

申请日：2021-02-26

申请人： Novartis AG

发明人： Diana GRAUS PORTA

IPC分类号： A61K31/506 ,  A61K31/497 ,  A61K31/4965

摘要： The present invention relates to a pharmaceutical combination comprising dabrafenib, an Erk-inhibitor and a SHP2 inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.

公开(公告)号：US20230089503A1

公开(公告)日：2023-03-23

申请号：US17858701

申请日：2022-07-06

申请人： NOVARTIS AG

发明人： Stephanie Kay DODD ,  Arnaud GRANDEURY ,  Emmanuel SUFFERT ,  Evgenia ROUSAKI

IPC分类号： C07D401/14

摘要： The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

公开(公告)号：US11607486B2

公开(公告)日：2023-03-21

申请号：US16494231

申请日：2018-02-01

申请人： Novartis AG

发明人： Alain Schmidlin ,  Mario Iobbi ,  Erich Studer ,  Andrew Bryant ,  Chinmay Deodhar ,  Rajan Patel

IPC分类号： A61M5/142 ,  A61M5/145 ,  A61M5/158

摘要： The invention concerns an injector device (100), comprising access means (110, 115) configured to selectively allow and prevent a cartridge (120) storing a pharmaceutical product (122) from being removed from the injector device (100), a self-test unit (130) configured to cause a self-test of at least one of an electronic component and an electronic assembly of the injector device (100), and a control unit (140) configured to control the access means (110, 115) to allow the cartridge (120) to be removed from the injector device (100) in case the self-test has failed.

公开(公告)号：US20230085472A1

公开(公告)日：2023-03-16

申请号：US17645071

申请日：2021-12-20

申请人： Novartis AG

发明人： David CARCACHE ,  Florian GRUBER ,  Danilo GUERINI ,  Martin GUNZENHAUSER ,  Richard HENG ,  Francesca PERRUCCIO ,  Oliver SIMIC ,  Carsten SPANKA

IPC分类号： C07D401/14 ,  A61K45/06 ,  A61K31/4196 ,  A61K31/5377 ,  A61K31/454

摘要： The present disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using the same.

公开(公告)号：US20230052782A1

公开(公告)日：2023-02-16

申请号：US17784373

申请日：2020-12-11

申请人： Novartis AG

发明人： Frederick William HAMLIN ,  Anthony Jonathan BEDFORD ,  Duncan Aleck BISHOP ,  Andrew Murray GOW ,  David Stuart HARRIS ,  Nicholas Lee HAWSON ,  Jean-Paul KLEEVEN ,  Dominic LLOYD-LUCAS ,  David MUCIENTES ,  Martin Joseph MURPHY ,  Stephen PABOOJIAN

IPC分类号： A61M5/315 ,  A61M5/31

摘要： The present disclosure relates to an injection device, in particular a micro dose injection device such as, for example, an ophthalmic injection device. An example device comprises a rotatable plunger; a solution receptacle having a first end configured to slidably receive the rotatable plunger and a second end configured to dispense solution contained in the solution receptacle; a first stop member configured to prevent the rotatable plunger from being slidably displaced to a second position while the rotatable plunger is at a first position and in a first orientation; and a second stop member configured to prevent the rotatable plunger from rotating in a first direction about the first axis while the rotatable plunger is at the first position and in the first orientation, wherein slidably displacing the rotatable plunger from the first position to the second position dispenses a quantity of the solution contained in the solution receptacle.

公开(公告)号：US20230052629A1

公开(公告)日：2023-02-16

申请号：US17352734

申请日：2021-06-21

申请人： Novartis AG

发明人： Christopher Becker ,  Xiaolin Li ,  Peichao Lu ,  Naomi Samadara Rajapaksa ,  David Charles Tully ,  Xiaojing Michael Wang ,  Qian Zhao

IPC分类号： C07D471/04 ,  A61P31/22

摘要： The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

公开(公告)号：US11578130B2

公开(公告)日：2023-02-14

申请号：US16210480

申请日：2018-12-05

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC分类号： C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C07K14/74 ,  C12N9/12 ,  C12N9/90

摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US20230031406A1

公开(公告)日：2023-02-02

申请号：US17292881

申请日：2019-11-11

申请人： Novartis AG

发明人： Shomir GHOSH ,  Gary GLICK ,  Jason KATZ ,  William ROUSH ,  Hans Martin SEIDEL ,  Dong-Ming SHEN ,  Shankar VENKATRAMAN

IPC分类号： C07D409/12 ,  A61P1/00 ,  C07D417/12 ,  C07D221/16 ,  C07D401/12 ,  C07D221/18 ,  C07D498/04 ,  C07D471/04 ,  C07D498/20 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04 ,  C07D409/14 ,  C07H15/26

摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

公开(公告)号：US20230017087A1

公开(公告)日：2023-01-19

申请号：US17949016

申请日：2022-09-20

申请人： Novartis AG

发明人： Naveen DAKAPPAGARI ,  Jennifer BORDEAUX ,  Thai TRAN ,  Ju Young KIM

IPC分类号： G01N33/569 ,  G01N21/64 ,  G01N33/574 ,  C12Q1/6886 ,  C12Q1/6841

摘要： The invention relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.